Impact of Nirsevimab on bronchiolities in pediatric primary care in Lazio Region: an observational study

Abstract Background Bronchiolitis is the leading cause of lower respiratory tract infections in infants, with respiratory syncytial virus (RSV) as the primary pathogen. Nirsevimab, a long-acting monoclonal antibody, was introduced in Europe in late 2022 for RSV prophylaxis in all infants. In Italy,...

全面介紹

書目詳細資料

Principais autores:	Daniele Petrone, Ilaria Sani, Valentina De Vittori, Silvana Brenna, Pietro Luigi Rotili, Maria Teresa Fonte, On behalf of the Scientific Committee of the Italian Pediatrician Federation (FIMP), Rome, Italy
格式:	Artigo
語言:	Inglês
出版:	BMC 2026-03-01
叢編:	Italian Journal of Pediatrics
主題:	Nirsevimab Immunization RSV Prevention
在線閱讀:	https://doi.org/10.1186/s13052-026-02221-w
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!